Eckert & Ziegler and GlyTherix Sign Lutetium-177 Supply Agreement

Eckert & Ziegler Strahlen- Und Medizintechnik AG and GlyTherix Ltd have entered into a global clinical supply agreement. Eckert & Ziegler, a Berlin-based company, will provide Lutetium-177 chloride to GlyTherix for its clinical trials. These trials aim to develop treatments for aggressive cancers.

GlyTherix's approach uses Lu-177 with an antibody that targets Glypican-1, a protein found in several aggressive cancers. This includes prostate, pancreatic, bladder, lung, glioblastoma, and ovarian cancers. Their Australian Phase Ib trials are scheduled for early 2025, with US Phase II trials in 2026.

Eckert & Ziegler and GlyTherix are committed to advancing treatments for cancer patients. The partnership enhances GlyTherix's global supply capabilities, ensuring high-quality radioisotopes reach patients promptly.